Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1988 2
1989 3
1990 2
1992 1
1994 1
1996 1
1997 1
1998 1
1999 2
2000 1
2001 4
2002 6
2003 3
2004 3
2005 4
2006 2
2007 4
2008 4
2009 4
2010 7
2011 10
2012 2
2013 3
2014 9
2015 9
2016 7
2017 5
2018 6
2019 5
2020 5
2021 10
2022 5
2023 2
2024 8
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Zeiser R, et al. Among authors: chakraverty r. N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122. N Engl J Med. 2021. PMID: 34260836 Clinical Trial.
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G; REACH2 Trial Group. Zeiser R, et al. N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22. N Engl J Med. 2020. PMID: 32320566 Clinical Trial.
Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation.
Galleu A, Riffo-Vasquez Y, Trento C, Lomas C, Dolcetti L, Cheung TS, von Bonin M, Barbieri L, Halai K, Ward S, Weng L, Chakraverty R, Lombardi G, Watt FM, Orchard K, Marks DI, Apperley J, Bornhauser M, Walczak H, Bennett C, Dazzi F. Galleu A, et al. Among authors: chakraverty r. Sci Transl Med. 2017 Nov 15;9(416):eaam7828. doi: 10.1126/scitranslmed.aam7828. Sci Transl Med. 2017. PMID: 29141887 Free article.
Predictive Performance of Cardiovascular Risk Scores in Cancer Survivors From the UK Biobank.
McCracken C, Condurache DG, Szabo L, Elghazaly H, Walter FM, Mead AJ, Chakraverty R, Harvey NC, Manisty CH, Petersen SE, Neubauer S, Raisi-Estabragh Z. McCracken C, et al. Among authors: chakraverty r. JACC CardioOncol. 2024 Jul 23;6(4):575-588. doi: 10.1016/j.jaccao.2024.05.015. eCollection 2024 Aug. JACC CardioOncol. 2024. PMID: 39239345 Free PMC article.
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K… See abstract for full author list ➔ Mathew NR, et al. Among authors: chakraverty r. Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Nat Med. 2018. PMID: 29431743 Free PMC article.
Integrating patient and public involvement and engagement in translational medicine.
Shaw KL, Calvert MJ, Borrow P, Chakera E, Chakraverty R, Hughes SE, Khatsuria F, Kinsella FAM, McMullan C, Richardson-Abraham J, Yarosh V, Aiyegbusi OL. Shaw KL, et al. Among authors: chakraverty r. Lancet. 2024 Aug 31;404(10455):828-831. doi: 10.1016/S0140-6736(24)01552-6. Epub 2024 Aug 8. Lancet. 2024. PMID: 39128476 No abstract available.
Unraveling the Mechanisms of Cutaneous Graft-Versus-Host Disease.
Santos E Sousa P, Bennett CL, Chakraverty R. Santos E Sousa P, et al. Among authors: chakraverty r. Front Immunol. 2018 May 2;9:963. doi: 10.3389/fimmu.2018.00963. eCollection 2018. Front Immunol. 2018. PMID: 29770141 Free PMC article. Review.
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.
Zeiser R, Russo D, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hamad N, Burock K, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F. Zeiser R, et al. Among authors: chakraverty r. J Clin Oncol. 2025 Aug 10;43(23):2566-2571. doi: 10.1200/JCO-24-02477. Epub 2025 Jun 25. J Clin Oncol. 2025. PMID: 40561385 Free PMC article. Clinical Trial.
131 results